Pfizer's Plan B In Immuno-Oncology: Collaboration With Smaller Companies

25-06-2014 Seeking AlphaComments (0)

Corporate crimeDow Jones Industrial AverageHealth Medical PharmaOncologyPfizerPfizer

Pfizer (PFE) recently signed a contract with Cellectis, a French biotech company. [1] The deal involves a research collaboration between the two to develop cancer drugs that leverage the body's immune system to fight cancer cells. Under the contract terms, Pfizer will pay Cellectis an initial amount of $80 million and also finance its research and development. [1] In addition, the biotech firm may also receive additional payments on achieving development, regulatory approval and commercialization-related milestones. The deal underscores the importance of immuno-oncology drug development. Competitors such as Merck (MRK) and Bristol-Myers Squibb (BMY) appear to have more promising immuno-oncology drugs under development, and that could impact Pfizer in the near future. It makes sense for Pfizer to enter such collaborations, and perhaps even acquire smaller innovative biotech companies, given its recent falling out with AstraZeneca. Pfizer had initially tried to acquire AstraZeneca in

Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top